Health Technology · Pharmaceuticals: Major · NSE: CAPLIPOINT · data 2026-10-09
Caplin Point Laboratories Limited
Health check: Strong (8.1/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹2,460.8
Market cap
₹19,388 cr
P/E
28.2
P/B
—
ROE
19.9%
ROCE
20.9%
Debt / equity
0
Dividend yield
0.31%
1-year return
21.8%
52-week high
₹2,990
52-week low
₹1,500.3
Operating margin
31.4%
Growth
| Revenue (last 12 months) | ₹2,287 cr |
| Net profit (last 12 months) | ₹665 cr |
| Sales growth, 3 years (yearly) | 14.3% |
| Profit growth, 3 years (yearly) | 19.4% |
Similar companies
Shilpa Medicare Limited (SHILPAMED) · PFIZER LIMITED (PFIZER) · OneSource Specialty Pharma Limited (ONESOURCE) · Cohance Lifesciences Ltd (COHANCE) · Alivus Life Sciences Ltd (ALIVUS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open CAPLIPOINT in NSE Scanner →